SCHEMBL3014620

SCHEMBL3014620

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4cccc(C)c4C)cs3)CC2)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
RECQL P46063 2/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 2/20 0.52
ALDH1A1 P00352 6/20 0.52
REV1 Q9UBZ9 1/20 0.46
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.44
HTT P42858 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
PKM P14618 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 2/20 0.43
LMNA P02545 4/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017484 0.93 ALDH1A1 (0.62) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3014233 0.93 MAPT (0.54) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3010536 0.90 MAPT (0.54) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3008901 0.89 MAPT (0.55) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3011444 0.88 MAPT (0.53) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3010407 0.87 REV1 (0.57) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3005891 0.86 AR (0.53) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3017985 0.86 MAPT (0.61) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3014033 0.86 MAPT (0.43) MAPTRECQLHSD17B10USP2ALDH1A1
SCHEMBL3004687 0.85 ALDH1A1 (0.61) MAPTRECQLHSD17B10USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.